Mega-analysis of 400 THC infusions confirms THC induces psychosis-like symptoms in nearly half of healthy volunteers
Pooling data from 10 studies with 400 intravenous THC infusions in healthy volunteers, clinically meaningful psychosis-like symptoms occurred in 45% of infusions, with effects increasing with dose and decreasing with frequent prior cannabis use.
Quick Facts
What This Study Found
44.75% of THC infusions produced clinically meaningful positive psychosis symptoms. Conceptual disorganization, hallucinations, blunted affect, and poor attention were most frequently affected. Higher THC doses increased symptoms, while frequent prior cannabis use blunted them.
Key Numbers
400 IV THC infusions across 10 studies. 44.75% showed clinically meaningful positive symptom increases. Dose association: beta=11.13. Frequent cannabis use association: beta=-0.575. Strong correlation with perceptual alterations (rs=0.514).
How They Did This
Individual participant-data mega-analysis of 10 double-blind, randomized, placebo-controlled crossover studies using intravenous THC infusions in healthy volunteers. The PANSS (Positive and Negative Syndrome Scale) measured psychotomimetic effects.
Why This Research Matters
This is the most comprehensive analysis of THC-induced psychosis-like effects in controlled settings, confirming the dose-dependent relationship and demonstrating that tolerance from regular use partially protects against these effects.
The Bigger Picture
The finding that frequent cannabis users show blunted psychotomimetic responses suggests tolerance develops to these effects, which may partly explain why most regular users do not develop psychotic disorders despite repeated exposure to a psychotomimetic substance.
What This Study Doesn't Tell Us
Intravenous THC administration does not replicate real-world cannabis use (smoking, edibles). Participants were healthy volunteers, not people at high risk for psychosis. The controlled setting may moderate psychological responses.
Questions This Raises
- ?What distinguishes the 45% who had psychosis-like symptoms from the 55% who did not?
- ?Does the tolerance that blunts psychotomimetic effects also protect against long-term psychosis risk?
Trust & Context
- Key Stat:
- 45% of THC infusions produced clinically meaningful psychosis-like symptoms
- Evidence Grade:
- Strong: individual participant-data mega-analysis of 10 controlled studies with 400 infusions.
- Study Age:
- Published in 2020 in International Journal of Neuropsychopharmacology.
- Original Title:
- Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.
- Published In:
- The international journal of neuropsychopharmacology, 23(9), 559-570 (2020)
- Authors:
- Ganesh, Suhas(5), Cortes-Briones, Jose(3), Ranganathan, Mohini(13), Radhakrishnan, Rajiv, Skosnik, Patrick D, D'Souza, Deepak Cyril
- Database ID:
- RTHC-02567
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Does THC cause psychosis in everyone?
No. Even in this controlled setting with intravenous THC (which produces stronger effects than smoking), only about 45% of infusions produced clinically meaningful psychosis-like symptoms. The effects were temporary and resolved after the drug wore off.
Why do regular cannabis users have weaker reactions?
Frequent cannabis use was associated with a blunted psychotomimetic response, likely reflecting tolerance. The brain adapts to regular THC exposure by adjusting cannabinoid receptor sensitivity, which dampens acute psychosis-like effects.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-developing-brain-teenagers
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cant-enjoy-anything-without-weed
- cross-addiction-quit-weed-start-drinking
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- is-weed-addictive
- is-weed-addictive-science
- nervous-system-weed-withdrawal-fight-flight
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-02567APA
Ganesh, Suhas; Cortes-Briones, Jose; Ranganathan, Mohini; Radhakrishnan, Rajiv; Skosnik, Patrick D; D'Souza, Deepak Cyril. (2020). Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.. The international journal of neuropsychopharmacology, 23(9), 559-570. https://doi.org/10.1093/ijnp/pyaa031
MLA
Ganesh, Suhas, et al. "Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.." The international journal of neuropsychopharmacology, 2020. https://doi.org/10.1093/ijnp/pyaa031
RethinkTHC
RethinkTHC Research Database. "Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydro..." RTHC-02567. Retrieved from https://rethinkthc.com/research/ganesh-2020-psychosisrelevant-effects-of-intravenous
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.